PATENT ABSTRACTS I 1 7

4485177 4486408

C R E A T I N I N E S P E C I F I C A N T I B O D Y

Joachim Siedel, Ulrich Neumann, Joachi Ziegenhorn, Hans-George Batz, Helmut Lenz, Brigitte Pautz, Winfried Albert, Bernried, Federal Republic Of Germany assigned to Boehringer Mannheim GmbH

The present invention provides a creatinine anti- body and a process for the preparation thereof, wherein a conjugate of creatinine and a material suitable for antiserum formation, which are con- nected via an aliphatic or araliphatic carboxylic acid as bridge member, is used as immunogen for antiserum formation. The present invention is also concerned with the use of the above anti- body for the immunological determination of creatinine, wherein the antibody is incubated with a creatinine+containing sample solution, reacted with a conjugate ofcreatinine with a hap- ten carrier substance, whereby one of the compo- nents, antibody and conjugate, is present in the solid phase or in dissolved form and the other component is present in dissolved form and the inhibition of the binding reaction between the antibody and the creatinine conjugate is measured. Furthermore, the present invention provides a reagent for the immunological deter- mination of creatinine, wherein it contains the above antibody, a conjugate of creatinine with a hapten carrier substance and buffer substance.

I N S O L U B L E C R O S S L I N K E D C Y T O T O X I C O X I D A S E - P E R O X I D A S E S Y S T E M

Johnathan Kiel, Johannes Everse

A therapeutic preparation, and a process of using the preparation, for the control of tumor growth and immune diseases. The preparation is an immobilized cytotoxic enzyme system which is carried by an insoluble substrate that is ad- ministered into the mammalian subject by injec- tion or implantation. The preferred embodiment of the preparation uses a polymerized albumin carrier containing immobilized glucose oxidase and peroxidase. The immobilized enzyme system is prepared in the form of small particles that can be administered either by implantation or by in- jection into tumor-bearing mammals. To date, antibacterial activity has been demonstrated only in vitro. Intraperitoneal injection into rats bearing Novikoff hepatomas or into mice bearing B16-FI melanomas or L1210 (Lymphoid) tumors has resulted in the selected killing of tumor tissues. Several daily ad- ministrations are required to achieve complete destruction of the tumor. Additionally, the pre- paration is also active as a stimulant of the specific immune response to neoplasia. Its effect on the immune system could be useful in the stimulation of the immune system in diseases where the action of the endogenous immune sys- tem is insufficient.

4486344

U R E A - L I N K E D I M M U N O G E N S , A N T I B O D I E S , A N D

P R E P A R A T I V E M E T H O D

Robert T Buckler assigned to Miles Laboratories Inc

hapten(amino-~ C "-~-'(- NH)Carner

Immunogen conjugates comprising amino- functionalized haptens coupled through a car- bonyl bridge to amino groups in immunogenic proteins and polypeptides. The resulting simple urea linkage in the conjugate is hydrophilic and contributes essentially no haptenic deter- minants. The immunogen is characterized by a high epitopic density. The method involves reac- tion of the hapten with a carbonyl diimidazole followed by addition of the protein or poly- peptide carrier. Protein crosslinking problems common to prior art coupling methods are avoided.

448~09

I N D U C E R O F T - S U P P R E S S O R C E L L S

Marcia F Goldfarb

This invention relates to a new composition of matter, and more particularly to a novel thymic factor isolated in purified form from mammalian thymus tissue which induces immature bone marrow cells to differentiate into competent sup- pressor T-cells (Ts). This novel thymic factor, which can also be called inducer of T-suppressor cells (iTs), has a molecular weight of approx- imately 65,000 daltons, as determined by gel fil- tration, a pl of 4.2-4.5, and is heat stable up to about 80 degrees C. iTs induces immature bone marrow cells to differentiate into cells which ex- hibit a phenotypic marker of suppressor T-cells and which when adoptively transferred repress reconstitution of the immune response in ir- radiated, thymectomized mice. An antibody has also been raised to iTs. This invention also relates to therapeutic methods and fields of use for iTs.